Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Mayville Engineering Company Q4 2025 Earnings Call - Data center ramp drives short-term margin pain, sets stage for >20% revenue mix in 2026
MEC called Q4 a transitional quarter. Management reallocated capacity to support an accelerating data center and critical power ramp after the Accu-Fab acquisition, which drove top-line growth but pro...
- Q4 sales rose 10.7% year over year to $134.3 million, but organic sales excluding Accu-Fab declined 5.3%.
- Margin hit was explicit and quantified, manufacturing margin fell to 6.6% from 8.9% last year, and Adjusted EBITDA margin declined to 4.7% from 7.6%.
- Management attributes margin pressure to transitory items, specifically $1.2 million of data center launch costs and $1.7 million of early-stage commercial vehicle project inefficiencies.
- +12 more takeaways
Dycom Industries Fourth Quarter 2026 Earnings Call - Record revenue and Power Solutions deal pushes Dycom into data center and fiber markets
Dycom closed fiscal 2026 with record revenue and a stretched backlog, while using a large acquisition to pivot into the data center ecosystem. The quarter and year delivered top-line beats, margin exp...
- Q4 FY2026 revenue hit a record $1.458 billion, up 34.4% year-over-year, with organic Q4 growth of 16.6% after adjusting for Power Solutions and the extra fiscal week.
- Full-year FY2026 revenue set a record at $5.55 billion, up 17.9% year-over-year, with organic revenue up 6.5% for the year.
- Adjusted EBITDA for Q4 was $162.4 million, with an adjusted EBITDA margin of 11.1%, up about 41 basis points year-over-year. Full-year adjusted EBITDA was $737.7 million, with a margin of 13.3%, up 105 basis points versus FY2025.
- +16 more takeaways
Ocugen Q4 2025 Earnings Call - OCU400 rolling BLA to start in Q3 2026 after completing liMeliGhT enrollment; top-line Phase III data due Q1 2027
Ocugen closed 2025 with enrollment complete in its broad, gene-agnostic OCU400 Phase III liMeliGhT study and positive long-term Phase I/II durability data, and management plans to begin a rolling BLA ...
- OCU400 (retinitis pigmentosa) enrollment complete in the Phase III liMeliGhT trial: 140 patients randomized 2:1 across gene-specific and gene-agnostic arms; primary endpoint is 12-month change in Luminance Dependent Navigation Assessment (LDNA).
- Management expects to start a rolling BLA submission for OCU400 in Q3 2026, with top-line Phase III data anticipated in Q1 2027 and potential approval in 2027 if data support filing.
- Long-term Phase I/II OCU400 data show sustained ~two-line LLVA gain at three years, with no new treatment-related serious adverse events reported, supporting durability and safety claims.
- +12 more takeaways
Cellectar Biosciences Fourth Quarter and Full Year 2025 Earnings Call - Iopofosine advances toward EU CMA and US Accelerated Approval after 12-month data
Cellectar finished 2025 with regulatory clarity and a narrowed path to market for its lead radiotherapeutic, iopofosine I 131. Management says they now have 12 months of follow-up on all CLOVER-WaM pa...
- Iopofosine I 131 is the lead asset, and Cellectar plans to submit a Conditional Marketing Authorisation application to the EMA in Q3 2026, targeting potential European commercialization as early as 2027.
- Company reports 12 months of follow-up on all CLOVER-WaM patients, and management says the mature data show improved response rates, durability, progression-free survival, and duration of response versus the December 2024 cut.
- Cellectar intends to pursue US Accelerated Approval under its Breakthrough Therapy designation, with an NDA submission shortly after initiating the confirmatory Phase III in a post-BTKi, second-line population.
- +17 more takeaways
Riskified Q4 2025 Earnings Call - First GAAP-profitable quarter, record revenue and a shift to gross profit-led growth
Riskified closed Q4 2025 with record quarterly revenue near $100 million and its first-ever GAAP profitable quarter, underscoring improving unit economics even as top-line growth remains modest. Manag...
- Record Q4 revenue of $99.3 million, and full-year 2025 revenue of $344.6 million, up 6% and 5% year-over-year respectively.
- Q4 non-GAAP gross profit was $57.3 million, up 16% year-over-year; full-year non-GAAP gross profit was $180.3 million, up 4% year-over-year.
- Company reported its first-ever GAAP profitable quarter with Q4 net profit of $5.8 million, versus a -$4.1 million loss in prior-year Q4.
- +17 more takeaways
Stevanato Group Q4 2025 Earnings Call - GLP-1s and High-Value Solutions Drive Margin Expansion as Engineering Lags
Stevanato closed fiscal 2025 with a clear bifurcation. The Biopharmaceutical and Diagnostic Solutions business accelerated, led by GLP-1 demand and other high-value offerings, pushing gross margins hi...
- Fiscal 2025 total company revenue rose 9% at constant currency and 7% on a reported basis versus 2024.
- Biopharmaceutical and Diagnostic Solutions (BDS) delivered double-digit growth in 2025, offsetting an expected decline in engineering.
- High-Value Solutions grew 29% in fiscal 2025 and represented about 46% of full-year company revenue.
- +12 more takeaways
National Vision Q4 FY2025 Earnings Call - Transformation drove margin expansion as premium mix and managed-care growth reshape the business
National Vision closed fiscal 2025 with clear proof that its multi-year transformation is working: revenue of $1.99 billion, adjusted comparable store sales +6% for the year, and adjusted operating in...
- Fiscal 2025 results show tangible progress: net revenue $1.99 billion, adjusted comparable store sales +6%, adjusted operating income $102.5 million, AOI margin 5.2%, and adjusted EPS $0.80 versus $0.52 in 2024.
- Q4 highlights: net revenue $503 million (+15.1% y/y, includes 53rd week impact elsewhere), adjusted comps +4.8%, adjusted operating income $17.6 million and adjusted EPS $0.15 versus a loss of $0.04 last year.
- The 53rd week boosted results materially: week 53 represented $35.6 million of net revenue and $3.5 million of adjusted operating income. Comparable metrics are reported on a 52-week basis.
- +13 more takeaways
VersaBank Q1 2026 Earnings Call - US SRP Momentum Targets CAD 1B Fundings, Driving Record Assets and Operating Leverage
VersaBank opened fiscal 2026 with punch, driven by an accelerating U.S. Structured Receivable Program that produced over CAD 200 million of fundings in Q1 and lifted credit assets and revenue to recor...
- U.S. Structured Receivable Program (SRP) drove the quarter, with more than CAD 200 million of additional fundings in Q1 and management targeting at least CAD 1 billion of new fundings in fiscal 2026.
- Credit assets reached a record CAD 5.33 billion at quarter end, with the SRP portfolio at CAD 4.4 billion, representing 83% of total credit assets.
- Total consolidated revenue hit a record CAD 36.5 million, up 31% year-over-year and 4% sequentially, reflecting SRP momentum and asset growth.
- +12 more takeaways
EyePoint Pharmaceuticals Fourth Quarter 2025 Earnings Call - DURAVYU on track for mid-2026 wet AMD top-line; cash runway to Q4 2027
EyePoint closed 2025 with clear focus and deliberate execution, centering the company on DURAVYU as a potential durable blockbuster for wet AMD and DME. Management reports both LUGANO and LUCIA Phase ...
- DURAVYU Phase 3 wet AMD program (LUGANO and LUCIA) is progressing, with top-line results expected beginning mid-2026.
- First patients dosed in two pivotal Phase 3 DME trials, COMO and CAPRI; topline DME data expected in the second half of 2027.
- EyePoint reports a favorable cumulative safety profile across ~191 patients: no ocular or systemic SAEs attributed to DURAVYU and no reported uveitis or vitritis.
- +13 more takeaways
Holley Performance Brands Q4 & FY 2025 Earnings Call - Core Growth Every Quarter, >20% Adjusted EBITDA and Leverage <3.8x
Holley closed 2025 with a disciplined reset that finally shows up in the numbers. For the first time since 2021 the company delivered full-year reported net sales growth while pushing adjusted EBITDA ...
- Holley delivered full-year net sales of $613.5 million in 2025, the first annual top-line growth since 2021, with core net sales up ~6.6% for the year.
- The company achieved adjusted EBITDA of $124.0 million for FY2025, driving adjusted EBITDA margin above 20% (20.2%) for the first time since 2021.
- Core business grew in every quarter of 2025, accelerating to 13.5% core growth in Q4; Q4 net sales were $155.4 million, up 10.9% year-over-year.
- +13 more takeaways